Using phosphorus-32 (P-32) radiopharmaceutical for treatment of bone pain in cancer patients with skeletal metastases

Using phosphorus-32 (P-32) radiopharmaceutical for treatment of bone pain in 60 cancer patients with skeletal metastases (34 males, 26 females) showed that: The analgesia effect of P-32 was remarkable, 86.67% patients had good results, the bone pain was dicreased for long time. The patients's quality of life was more improved. The KPI before treatment was 51.83 and after treatment 3 months = 66.92. The toxicity was slight and under control : Amount of red blood cells and plates were slightly dicreased. It become normal after P-32 treatment 6-8 weeks. Nothing changed before and after treatment with white blood cells and the bio-chemistic criterias. The impact and side effects for the body were not significantly.